Acerta Pharma Bv

This early-phase study tests a new drug combination for people with untreated mantle cell lymphoma, a rare blood cancer. Participants receive acalabrutinib plus either bendamustine and rituximab or venetoclax and rituximab. The main goal is to check safety and side effects, not t…

This study tests a drug called acalabrutinib, alone or with other medicines, in 113 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the drug is safe and shrinks tumors. This is an early-phase trial, so it focus…

This phase 2 study tested a drug called acalabrutinib (ACP-196) in 124 adults with mantle cell lymphoma that had returned or stopped responding to prior therapy. The main goal was to see how many patients had their tumors shrink or disappear (overall response rate). The drug is t…

This early-phase study tests a new drug combination (ceralasertib plus acalabrutinib) in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The main goal is to check safety and find the right dose. Participants mus…

This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had to stop ibrutinib because of side effects. The main goal is to see how many patients' tumors shrink or disa…

This study tested a new drug called acalabrutinib against two standard treatments for people with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to prior therapy. About 310 adults took part. The main goal was to see if acalabrutinib could delay cancer…

This study tests a drug called acalabrutinib in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the drug can shrink tumors and control the disease. Participants take the pill daily, and researchers monitor safety and response.

This study tests whether adding the drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a certain type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). About 611 adults aged 18 to 75 are participating. The main goal is to see if the combination delay…

This phase 3 study compares two oral medications, acalabrutinib and ibrutinib, in adults with high-risk chronic lymphocytic leukemia (CLL) who have already received at least one prior treatment. The goal is to see if acalabrutinib is as effective as ibrutinib at delaying cancer p…

This study tests a drug called ACP-196 (acalabrutinib) in adults whose glioblastoma brain tumor has come back after standard treatment. The goal is to see if the drug can shrink or control the tumor. About 24 participants will receive the drug, and their response will be measured…

This study tests a new drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal is to see if the drug is safe and can shrink or control the cancer. Participants take the drug by mouth, and the study tracks side effects and ho…

This study tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer getting worse. About 635 adults aged 65 and older will take part. The goal is to…